Equillium, Inc. (NASDAQ:EQ) Short Interest Up 245.6% in January

Equillium, Inc. (NASDAQ:EQ) was the target of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 93,300 shares, an increase of 245.6% from the January 15th total of 27,000 shares. Based on an average daily volume of 771,800 shares, the short-interest ratio is presently 0.1 days. Currently, 0.5% of the shares of the company are sold short.

Equillium Stock Down 1.2 %

EQ traded down $0.01 during trading hours on Wednesday, hitting $0.88. The stock had a trading volume of 193,832 shares, compared to its average volume of 1,626,384. Equillium has a 1 year low of $0.49 and a 1 year high of $3.25. The company’s fifty day simple moving average is $0.70 and its 200 day simple moving average is $0.81. The stock has a market cap of $31.11 million, a PE ratio of -6.27 and a beta of 1.79.

Hedge Funds Weigh In On Equillium

An institutional investor recently bought a new position in Equillium stock. Takeda Pharmaceutical Co. Ltd. bought a new stake in shares of Equillium, Inc. (NASDAQ:EQ) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 1,824,977 shares of the company’s stock, valued at approximately $1,369,000. Equillium accounts for about 5.2% of Takeda Pharmaceutical Co. Ltd.’s portfolio, making the stock its 4th biggest holding. Takeda Pharmaceutical Co. Ltd. owned about 5.15% of Equillium as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 27.05% of the company’s stock.

Equillium Company Profile

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.